Changes to the NASDAQ Biotech Index
Bring out your dead... Bring out your dead...
NASDAQ recently announced the companies to be added and subtracted from the NASDAQ Biotech Index (NBI) and the IBB ETF effective November 21, 2005.
I also note that Eyetech (EYET) comes out due to its acquisition by OSI Pharma (OSIP). After all the shuffling is done, there will be 161 companies in the index.
AEZS - Aeterna-Zentaris
CGTK - Corgentech
CIPH - Ciphergen Biosystems
GTXI - GTx, Inc.
LJPC - LaJolla Pharmaceuticals
NVAX - NovaVax
PRCSD - Praecis Pharmaceuticals
(descriptions are from the NASDAQ press release):
Alnylam Pharmaceuticals, Inc. (ALNY) is a biotechnology company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi.
Anadys Pharamceuticals, Inc. (ANDS) provides biopharmaceuticals. The company discovers, develops, and commercializes small molecule, anti-infective medicines for the treatment of HCV and bacterial infections.
BioCryst Pharmaceuticals, Inc. (BCRX) a biopharmaceutical company, discovers and designs novel small molecule pharmaceuticals using structure-based drug design. The company's products are used for the treatment of immunological, viral, and cardiovascular diseases and disorders.
Crucell N.V. (CRXL) licenses technology to pharmaceutical and biotechnology companies. Crucell develops treatments for cancer, inflammatory diseases, and influenza.
CoTherix, Inc. (CTRX) is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and chronic diseases.
DURECT Corporation (DRRX) develops and commercializes pharmaceutical systems for the treatment of chronic diseases.
Gen-Probe Incorporated (GPRO) develops, manufactures, and commercializes diagnostic products based on its generic probe technologies. The company's products are used for the clinical diagnosis of human diseases and for screening donated human blood.
Hi-Tech Pharmacal Co., Inc. (HITK) manufactures prescription and over-the-counter generic and branded pharmaceuticals in liquid and semi-solid dosage forms.
Kosan Biosciences Incorporated (KOSN) is a biotechnology company that develops drugs from molecules called polyketides.
Momenta Pharmaceuticals, Inc. (MNTA) is a biotechnology company specializing in sequencing and engineering of complex sugars for the development of novel drugs, and discovery of new biological processes.
Nastech Pharmaceutical Company Inc. (NSTK) researches, develops and manufactures nasally administered pharmaceuticals.
Panacos Pharmaceuticals, Inc. (PANC) is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases.
Sirna Therapeutics, Inc. (RNAI) is a biotechnology company utilizing its expertise in nucleic acid technology to develop and commercialize products that target human diseases.
Renovis, Inc. (RNVS) is a biopharmaceutical company developing drugs to treat neurological diseases and disorders.
StemCells, Inc. (STEM) is a biotechnology company. The company discovers, develops, and commercializes stem cell-based therapies to treat diseases of the central nervous system, liver, and the pancreas.
ViaCell, Inc. (NASDAQ:VIAC) is a biotechnology company focused on enabling the widespread use of human cells as medicine. In addition to its therapeutic focus, the company offers expecting families the opportunity to preserve umbilical cord blood for potential future medical use.
ViroPharma Incorporated (VPHM) is a pharmaceutical company committed to the development and commercialization of medicines for use by gastroenterologists, hepatologists, and in transplant and hospital settings.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter